[1]Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108. [2]Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012[J]. Eur J Cancer,2013, 49:1374-1403. [3]Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis[J]. Breast Cancer Res Treat, 2012, 133:1169-1177. [4]Smyth PP. The thyroid and breast cancer[J]. Curr Opin Endocrinol Diabetes Obes, 2016, 23:389-393. [5]高明,郑向前. 甲状腺癌过去与未来十年[J]. 中国肿瘤临床,2018, 45:2-6. [6]黄剑波, 金梁斌, 孔令泉, 等. 乳腺癌患者治疗期间甲状腺功能的变化研究[J]. 重庆医科大学学报, 2014, 38:57-60. [7]Khan MA, Bhurani D, Agarwal NB. Alteration of thyroid function in indian HER 2-negative breast cancer patients undergoing chemotherapy[J]. Asian Pac J Cancer Prev, 2015, 16:7701-7705. [8]Shi Y, Li X, Ran L, et al. Study on the status of thyroid function and thyroid nodules in chinese breast cancer patients[J].Oncotarget, 2017, 8:80820-80825. [9]刘倩欣, 向倩, 张卓, 等. 乳腺癌患者化疗药物不良反应情况及影响因素分析[J]. 中国临床药理学杂志, 2018, 34:475-478. [10]Li Y, Jiang D, Wu YY, et al. A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer[J]. 中华肿瘤杂志, 2017, 39:607-612. [11]Ortega-Olvera C, Ulloa-Aguirre A, Angeles-Llerenas A, et al. Thyroid hormones and breast cancer association according to menopausal status and body mass index[J]. Breast Cancer Res, 2018, 20:94-107. [12]Dong L, Lu J, Zhao B, et al. Review of the possible association between thyroid and breast carcinoma[J]. World J Surg Oncol, 2018, 16:130-136. |